Genomic advances and their impact on clinical trial design

Genome Medicine

Volumn 1, Issue 7, 2009, Pages

  Mandrekar, Sumithra J ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; TRASTUZUMAB; WARFARIN;

ADJUVANT THERAPY; BREAST CANCER; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COST; DRUG EFFICACY; FEASIBILITY STUDY; GENOMICS; HUMAN; METHODOLOGY; NOTE; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REPRODUCIBILITY; SAMPLING; VALIDATION PROCESS; WILD TYPE;

EID: 77953472144     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm69     Document Type: Note

References (39)

1. Conley BA, Taube SE: Prognostic and predictive markers in cancer. Dis Markers 2004, 20:35-43.
2. Taube SE, Jacobson JW, Lively TG: Cancer diagnostics: decision criteria for marker utilization in the clinic. Am J Pharmacogenomics 2005, 5:357-364.
3. Sequist LV, Bell DW, Lynch TJ, Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007, 25:587-595.
4. Bonomi PD, Buckingham L, Coon J: Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007, 13:s4606-s4612.
5. Slamon D: Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs 2000, 4(Sa):24-29.
6. Paik S: Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnol Annu Rev 2003, 9:259-267.
7. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS: Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 2009, 15:502-510.
8. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG: A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008, 7:3141-3149.
9. Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 2008, 105:19432-19437.
10. Anguiano A, Nevins JR, Potti A: Toward the individualization of lung cancer therapy. Cancer 2008, 113(Suppl 7):1760-1767.
11. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A: An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 2008, 3:e1908.
12. Garman KS, Nevins JR, Potti A: Genomic strategies for personalized cancer therapy. Hum Mol Genet 2007, 16:R226-R232.
13. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007, 8:1071-1078.
14. Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery IC, Lee M, O'Connell MJ, Shak S, Wolmark N: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract]. J Clin Oncol 2009, 27:4000.
15. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol, in press.
16. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 2009, 19:530-542.
17. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ: Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 2005, 5:317-325.
18. Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005, 23:2020-2027.
19. Hoering A, Leblanc M, Crowley JJ: Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res 2008, 14:4358-4367.
20. Simon R, Maitournam A: Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004, 10:6759-6763.
21. Maitournam A, Simon R: On the efficiency of targeted clinical trials. Stat Med 2005, 24:329-339.
22. Wang SJ, O'Neill RT, Hung HMJ: Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007, 6:227-244.
23. Jiang W, Freidlin B, Simon R: Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007, 99:1036-1043.
24. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000, 355:1745-1750.
25. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, Iacopetta B: p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001, 7:1343-1349.
26. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
27. Paik S, Kim C, Jeong J, Geyer CE, Romond EH, Mejia-Mejia O, Mamounas EP, Wickerham D, Costantino JP, Wolmark N: Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 [abstract]. J Clin Oncol 2007, 25:511.
28. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24:3032-3038.
29. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRas is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
30. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
31. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008, 26:721-728.
32. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ: Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
33. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006, 3:540-551.
34. Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F: Individualization of therapy using MammaPrint: From development to the MINDACT trial. Cancer Genomics Proteomics 2007, 4:147-155.
35. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
36. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764.
37. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ: Bayesian adaptive design for targeted therapy development in lung cancer - a step towards personalized medicine. Clin Trials 2008, 5:181-193.
38. Esserman J, Perou C, Cheang M, DeMichele A, Carey L, van 't Veer LJ, Gray J, Petricoin E, Conway K, Berry D: Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) [abstract]. J Clin Oncol 2009, 27:LBA515.
39. Lin C, Moore D, DeMichele A, Ollila D, Montgomery L, Liu M, Krontiras H, Gomez R, Esserman L: Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening [abstract]. J Clin Oncol 2009, 27:1503.